New insights on the pathogenesis of biliary cirrhosis provided by studies in FXR knockout mice

Michel Fausther1, Jonathan A Dranoff

  • 1Division of Gastroenterology & Hepatology, University of Arkansas for the Medical Sciences, Little Rock, AR 72205, USA.

Journal of Hepatology
|June 16, 2011
PubMed

Insights

Genetic ablation of the farnesoid X receptor (FXR) significantly reduced biliary fibrosis in mice. FXR loss did not impact non-cholestatic liver fibrosis, suggesting FXR

Area of Science:

  • Hepatology and Gastroenterology
  • Molecular Biology
  • Pharmacology

Background:

  • The nuclear bile acid receptor, farnesoid X receptor (FXR), is investigated for its role in liver fibrosis.
  • This study examines the impact of genetic FXR ablation on liver fibrosis using four distinct mouse models.

Discussion:

  • FXR protein was undetectable in mouse and human hepatic stellate cells (HSCs) and portal myofibroblasts (MFBs).
  • FXR loss significantly reduced liver fibrosis in models of biliary type (common bile duct ligation, 3,5-diethoxycarbonyl-1,4-dihydrocollidine).
  • FXR ablation had no effect on non-cholestatic liver fibrosis induced by CCl(4) intoxication or Schistosoma mansoni infection.

Key Insights:

  • FXR plays a critical role in the pathogenesis of biliary fibrosis.
  • FXR does not appear to influence non-cholestatic liver fibrosis.
  • HSCs and MFBs, lacking FXR expression, may not be direct therapeutic targets for FXR ligands in liver fibrosis.

Outlook:

  • These findings suggest FXR-targeted therapies may be beneficial for specific types of liver fibrosis.
  • Further research is needed to elucidate the mechanisms underlying FXR's role in biliary fibrosis.
  • The lack of FXR expression in HSCs/MFBs warrants exploration of alternative therapeutic strategies for liver fibrosis.